Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,160.31 +12.39 0.58%
FTSE 100 5,391.14 +34.80 0.65%
DAX 6,396.84 +73.65 1.16%
Ticker Volume Price Price Delta
Nikkei 8,601.13 -55.95 -0.65%
TOPIX 721.44 -5.59 -0.77%
Hang Seng 18,712.70 -342.72 -1.80%
Gold 1,551.40 +0.03%
EUR-USD 1.2466 -0.2981%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,391.14 +0.65%
STOXX 50 2,160.31 +0.58%
DAX 6,396.84 +1.16%
Oil (WTI) 90.32 -0.48%
U.S. 10-year 1.721% -0.024
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: ASE
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Mesoblast Ltd

Add to Portfolio

MSB:AU

6.4700 AUD 0.2300 3.43%

As of 01:45:29 ET on 05/30/2012.

Snapshot for Mesoblast Ltd (MSB)

Open: 6.6000 Day's Range: 6.4000 - 6.6200 Volume: 332,245 Bid: 6.4700
Previous Close: 6.7000 52wk Range: 6.0900 - 10.0400 1-Yr Rtn: -17.05% Ask: 6.4800

Stock Chart for MSB

No chart data available.
  • MSB:AU 6.4700
  • 1D
  • 1M
  • 1Y
6.7000
Interactive MSB Chart

Previous Close

Key Statistics for MSB

Current P/E Ratio (ttm) -
Estimated P/E (06/2012) -
Earnings Per Share (AUD) (ttm) -0.1684
Est. EPS (AUD) (06/2012) -0.1620
Est. PEG Ratio -
Market Cap (M AUD) 1,840.57
Shares Outstanding (M) 284.48
Enterprise Value (M AUD) (ttm) 1,599.73
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 3.6578
Price/Sale (ttm) -
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/24/2012
More MSB Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for MSB

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)
More MSB Income Statement Data
  • Total Assets
  • Total Liabilities (M/AUD)
  • Debt to Assets (%)
More MSB Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/AUD)
More MSB Cash Flow Data

Company Profile & Key Executives for MSB

Mesoblast Ltd., is a biotechnology company. The Company develops treatments for orthopaedic conditions, including the commercialisation of adult stem cells to regenerate, repair bone. and cartilage.

Brian JamiesonChairmanDonal P O'DwyerDeputy Chairman
Silviu ItescuCEO/Executive DirectorJenni PilcherCFO/Secretary
More Company Profile & Key Executives for MSB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements